3rd Annual Immunomodulatory Therapeutic Antibodies for Cancer

Recent regulatory approvals and a succession of favorable clinical data from the checkpoint inhibitor programs of major pharmas are now spearheading a new focus on immune system-modulating antibody therapeutics. These results are now driving interest across academic and industry research into a next generation of checkpoint blockades and co-stimulatory factors, and the application of these to additional tumor types and in exciting new roles in combination treatment regimens. For 2015, CHI’s Third Annual Immunomodulatory Therapeutic Antibodies for Cancer will explore developments in mainstream and emerging targets in this space, review progress in the application of immunotherapy for difficult to treat cancers and consider different concepts for developing multifunctional antibody immunotherapies.